Rallybio slashes workforce as it narrows focus on Phase II-ready programmes
临床1期临床2期
"We believe that these difficult, but necessary decisions to streamline our operations and align resources are critical to extend our cash runway…and put us on a path toward long-term success," said CEO Stephen Uden. The company estimates these actions will extend its cash runway into mid-2026.
Rallybio is developing RLYB212, an anti-HPA-1a antibody, to prevent foetal and neonatal alloimmune thrombocytopenia (FNAIT). Pending feedback from the European Medicines Agency (EMA), Rallybio says it continues to expect to initiate a Phase II study for RLYB212 in pregnant women at higher risk of FNAIT in the second half.
Last year, the company said preliminary data and the company's own clinical pharmacology modeling predictions supported a once-monthly dosing regimen for the planned Phase II study.
Meanwhile, RLYB116 is a once-weekly, subcutaneously injected complement C5 inhibitorcomplement C5 inhibitor in development for patients with complement-mediated diseases. Rallybio says it is "encouraged" by recent work on its manufacturing process that suggested the possibility of enhancing tolerability with higher doses of RLYB116.
"While the exposure levels of RLYB116 demonstrated in the Phase I study are expected to be suitable for the treatment of patients with generalised myasthenia gravis, the company believes ongoing enhancements will enable higher exposure to RLYB116, supporting the treatment of patients with a broader range of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria and antiphospholipid syndrome," it said.
Rallybio added that the actions are expected to fund its preclinical programme activities through to key 2024 milestones. These candidates include the MTP-2 inhibitor RLYB331 (KY1066), acquired via a deal with Sanofi, with data expected in the first half of 2024. The company is also working on an ENPP1 inhibitorENPP1 inhibitor with Exscientia, and the C5 inhibitor RLYB114 with EyePoint Pharmaceuticals.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。